Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06126276
Other study ID # NCI-2023-09270
Secondary ID NCI-2023-09270EA
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 7, 2024
Est. completion date April 30, 2025

Study information

Verified date May 2024
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.


Description:

PRIMARY OBJECTIVE: I. To investigate the efficacy of neratinib plus palbociclib (PD-0332991) compared to neratinib maleate (neratinib) alone in patients with HER2+ gynecologic cancers and HER2+ solid tumors by evaluating progression-free survival (PFS). SECONDARY OBJECTIVES: I. To investigate outcome in terms of objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. II. To investigate clinical benefit rate (ORR + stable disease at 16 weeks). III. To evaluate overall (OS) survival. IV. To evaluate the ORR of patients who crossed over from neratinib monotherapy to neratinib-palbociclib combination. V. To investigate adverse events especially grade 3 and 4 toxicities by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. VI. Collect tissue and provide it to the ComboMATCH Registration Protocol to assess concordance between the diagnostic tumor mutation profile generated by the Designated Laboratories, the pre-treatment biopsy mutation profile, and the pre-treatment circulating tumor-derived deoxyribonucleic acid (ctDNA) mutation profile from plasma, as described in ComboMATCH Registration Protocol. EXPLORATORY TRANSLATIONAL OBJECTIVES: I. To investigate the role of ctDNA-HER2 status at baseline and during follow up to assess if it predicts response to therapy and disease progression and if it does correlate with tumor tissue based HER2 status. II. To investigate if activation of the pathways of interest (PI3K/mTOR and RB1, CCND1-CDK4/6 CDK and RAS/RAF/MAPK) in tumor tissue as well as blood/ctDNA correlate with response or resistance to therapy. III. To correlate extent of HER2 amplification with response to treatment and with HER2 expression by immunohistochemistry or fluorescence in situ hybridization (FISH). IV. To correlate the extent of HER2 amplification with HER2 expression by RNA and protein immunohistochemistry (IHC) analyses and FISH. V. To correlate expression of Rb1, CCND1, CCNE1, CDK4/6 protein expression with response to treatment. VI. Assess alteration in RB1-CDK pathway in neratinib resistant patients at time of progression on monotherapy compared to combination neratinib-palbociclib. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive neratinib maleate orally (PO) once daily (QD) on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may crossover to Arm II. Patients undergo echocardiogram (ECHO) or multi-gated acquisition scan (MUGA) during screening and on study, and computed tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study. ARM II: Patients receive neratinib maleate PO QD on days 1-14 of cycle 0 in the absence of disease progression or unacceptable toxicity. Patients then receive neratinib maleate PO QD on days 1-28 and palbociclib PO QD on days 1-21 of each subsequent cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA during screening and on study, and CT or MRI and collection of blood samples throughout the trial. Patients may also undergo tumor biopsy during screening and on study. After completion of study treatment, patients are followed up every 3 months for 2 years.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date April 30, 2025
Est. primary completion date April 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N5 based on the presence of an actionable mutation as defined in EAY191 - Patients must have a HER2 amplified solid tumor except breast cancer. Patient's cancer must have HER2 amplification as defined with = 7 copies by next generation sequencing (NGS) testing - Patients must have recurrent or persistent disease - No known evidence of RB1 loss or deletion including copy number loss or deleterious mutation - Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or, if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191) - Patients must have measurable disease based on RECIST 1.1. A second measurable lesion outside of the biopsiable lesion is required - Patients with treated brain metastases are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression for 3 months or more and patient is not on steroids and is asymptomatic - No known leptomeningeal disease - Patients may have received up to 5 prior lines of systemic therapy - Prior therapy with trastuzumab or pertuzumab, either alone or in combination, is allowed - One prior line of anti-HER2 therapy is allowed except tyrosine kinase inhibitors (TKI) such as neratinib or tucatinib or antibody drug conjugates (ADC) such as DS8201a or T-DM1 - No prior therapy with CDK4/6 inhibition - No cancer directed therapy within 3 weeks prior to registration. For oral therapy, the washout can be reduced to greater than or equal to 5 half lives of the drug - Age = 18 - Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2 - Not pregnant and not nursing - Absolute neutrophil count (ANC) = 1,500 cells/mm^3 - Platelets = 100,000 cells/mm^3 - Hemoglobin = 9 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin (Hgb) = 9 g/dl is acceptable) - Creatinine clearance (CrCL) of = 30 mL/min by the Cockcroft-Gault formula - Total bilirubin level = 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level = 3 x institutional ULN may be enrolled) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 x institutional upper limit of normal (ULN) - Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better - No active infection requiring parenteral antibiotics - No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube - No current evidence of malabsorption or chronic diarrhea or any other significant gastro-intestinal disease (e.g gastrectomy, ileal bypass, Crohn's disease, gastroparesis), associated with moderate to severe diarrhea (grade 2 or more) or inability to tolerate oral therapy - No lung disease causing dyspnea at rest - No interstitial lung disease with ongoing signs and symptoms at the time of registration - No history of allergic reaction to the study agents, compound of similar chemical or biologic composition of the study agents or any of their excipients

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Biopsy
Undergo tumor biopsy
Biospecimen Collection
Undergo collection of blood samples
Computed Tomography
Undergo CT scan
Echocardiography
Undergo ECHO
Magnetic Resonance Imaging
Undergo MRI
Multigated Acquisition Scan
Undergo MUGA
Drug:
Neratinib Maleate
Given PO
Palbociclib
Given PO

Locations

Country Name City State
United States UPMC Altoona Altoona Pennsylvania
United States Community Hospital of Anaconda Anaconda Montana
United States Mission Cancer and Blood - Ankeny Ankeny Iowa
United States Trinity Health Saint Joseph Mercy Hospital Ann Arbor Ann Arbor Michigan
United States Duluth Clinic Ashland Ashland Wisconsin
United States National Institutes of Health Clinical Center Bethesda Maryland
United States Saint Alphonsus Cancer Care Center-Boise Boise Idaho
United States Bozeman Health Deaconess Hospital Bozeman Montana
United States Lafayette Family Cancer Center-EMMC Brewer Maine
United States Trinity Health IHA Medical Group Hematology Oncology - Brighton Brighton Michigan
United States Saint Alphonsus Cancer Care Center-Caldwell Caldwell Idaho
United States Trinity Health IHA Medical Group Hematology Oncology - Canton Canton Michigan
United States Saint Francis Medical Center Cape Girardeau Missouri
United States Miami Valley Hospital South Centerville Ohio
United States Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital Chelsea Michigan
United States John H Stroger Jr Hospital of Cook County Chicago Illinois
United States Southeastern Medical Oncology Center-Clinton Clinton North Carolina
United States Kootenai Health - Coeur d'Alene Coeur d'Alene Idaho
United States UPMC Western Maryland Cumberland Maryland
United States Dayton Physician LLC - Englewood Dayton Ohio
United States Miami Valley Hospital Dayton Ohio
United States Miami Valley Hospital North Dayton Ohio
United States Premier Blood and Cancer Center Dayton Ohio
United States Beaumont Hospital - Dearborn Dearborn Michigan
United States Cancer Care Specialists of Illinois - Decatur Decatur Illinois
United States Decatur Memorial Hospital Decatur Illinois
United States Essentia Health - Deer River Clinic Deer River Minnesota
United States Mission Cancer and Blood - Des Moines Des Moines Iowa
United States Essentia Health Cancer Center Duluth Minnesota
United States Crossroads Cancer Center Effingham Illinois
United States UPMC Hillman Cancer Center Erie Erie Pennsylvania
United States Beaumont Hospital - Farmington Hills Farmington Hills Michigan
United States Genesee Cancer and Blood Disease Treatment Center Flint Michigan
United States Genesee Hematology Oncology PC Flint Michigan
United States Genesys Hurley Cancer Institute Flint Michigan
United States Hurley Medical Center Flint Michigan
United States Atrium Medical Center-Middletown Regional Hospital Franklin Ohio
United States Southeastern Medical Oncology Center-Goldsboro Goldsboro North Carolina
United States Benefis Sletten Cancer Institute Great Falls Montana
United States Saint Vincent Hospital Cancer Center at Saint Mary's Green Bay Wisconsin
United States Saint Vincent Hospital Cancer Center Green Bay Green Bay Wisconsin
United States UPMC Cancer Centers - Arnold Palmer Pavilion Greensburg Pennsylvania
United States Miami Valley Cancer Care and Infusion Greenville Ohio
United States Essentia Health Hibbing Clinic Hibbing Minnesota
United States M D Anderson Cancer Center Houston Texas
United States Southeastern Medical Oncology Center-Jacksonville Jacksonville North Carolina
United States Kettering Medical Center Kettering Ohio
United States Gundersen Lutheran Medical Center La Crosse Wisconsin
United States University of Michigan Health - Sparrow Lansing Lansing Michigan
United States Trinity Health Saint Mary Mercy Livonia Hospital Livonia Michigan
United States UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion Mechanicsburg Pennsylvania
United States Community Medical Center Missoula Montana
United States UPMC Hillman Cancer Center - Monroeville Monroeville Pennsylvania
United States Saint Alphonsus Cancer Care Center-Nampa Nampa Idaho
United States Saint Vincent Hospital Cancer Center at Oconto Falls Oconto Falls Wisconsin
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Saint Alphonsus Cancer Care Center-Ontario Ontario Oregon
United States University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania
United States UPMC-Passavant Hospital Pittsburgh Pennsylvania
United States Kootenai Clinic Cancer Services - Post Falls Post Falls Idaho
United States William Beaumont Hospital-Royal Oak Royal Oak Michigan
United States Kootenai Clinic Cancer Services - Sandpoint Sandpoint Idaho
United States Essentia Health Sandstone Sandstone Minnesota
United States Saint Vincent Hospital Cancer Center at Sheboygan Sheboygan Wisconsin
United States Memorial Medical Center Springfield Illinois
United States Southern Illinois University School of Medicine Springfield Illinois
United States Springfield Clinic Springfield Illinois
United States Marshfield Medical Center-River Region at Stevens Point Stevens Point Wisconsin
United States Saint Vincent Hospital Cancer Center at Sturgeon Bay Sturgeon Bay Wisconsin
United States Upper Valley Medical Center Troy Ohio
United States William Beaumont Hospital - Troy Troy Michigan
United States Essentia Health Virginia Clinic Virginia Minnesota
United States Marshfield Medical Center - Weston Weston Wisconsin
United States Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus Ypsilanti Michigan

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival The stratified log-rank statistic will be used to draw inferences about the relative activity of the two regimens. Characterized by medians and Kaplan-Meier (KM) curves. From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 2 years
Secondary Overall survival The impact of treatment on the hazard of death can be investigated with time dependent covariates. Up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Active, not recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT04871542 - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A